About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 558 record(s)
Req # A-2022-000880
Information for all complaints posted against Bausch - in relation to health product advertising incidents. All information in relation to incidents received by Health Canada and those referred to an Advertising Preclearance Agency (APA) from 2019-01-01- 2022-09-27. All information in relation to complaints regarding the direct-to-consumer advertising of unauthorized claims.Organization: Health Canada
October 2023
Req # A-2022-001436
The total costs spent on catering by the department in 2020 and 2021.Organization: Health Canada
October 2023
Req # A-2022-001498
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient plerixafor. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for plerixafor which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
October 2023
Req # A-2022-001621
Studies or internal analysis detailing the prevalence of mental health diagnoses among Track 2 Medical Assistance In Dying (MAID) applicants between March 17, 2021 to March 29, 2023. Any internal studies or analysis about expansion of current MAID criteria to include mature minors.Organization: Health Canada
October 2023
Req # A-2023-000034
This is a request for any bench/electrical, animal, preclinical and clinical study data for CARL ZEISS MEDTEC AG’s Convivo System Medical Device Licence (MDL) No. 106067 submitted to the Medical Devices Directorate.Organization: Health Canada
October 2023
Req # A-2023-000073
All documents from discussions with Indigenous and Provincial governments and supportive documentation relating to the 2023 Federal Budget announcement that details the “The federal government is also making progress with Indigenous communities and organizations on a voluntary fuel, alcohol, cannabis, and tobacco (FACT) sales tax framework. Since fall 2022, productive discussions have taken place with Indigenous partners, and Indigenous communities have expressed interest in moving forward collaboratively. The federal government also continues to encourage, and will help facilitate, taxation arrangements between interested provincial or territorial and Indigenous governments.”Organization: Health Canada
October 2023
Req # A-2023-000167
COVID-19 impact reports of GEN-Clozapine. All marketed strengths of GEN-Clozapine (Drug Identificatoin Number (DIN) #s, 02247243, 02247244, 02305003 and 02305011).Organization: Health Canada
October 2023
Req # A-2023-000301
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Clinical Practice (GCP) inspection of the Merck Canada facility in Kirkland, Quebec, for the Region of Alberta starting around 25 May 2021. Reference Number 182348.Organization: Health Canada
October 2023
Req # A-2023-000302
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the Bausch & Lomb facility in Rochester, New York, United States of America starting around 6 December 2022. Reference Number 502442.Organization: Health Canada
October 2023
Req # A-2023-000303
Provide the disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the Merck Canada facility in Kirkland, Quebec, starting around 7 November 2022. Reference Number 502785.Organization: Health Canada
October 2023